Numerate racks up $5.5M for drug engineering technology
Numerate, a San Bruno, Calif.-based biotech company that streamlines pharmaceutical production pipelines and intellectual property protections, brought in $5.5. million in a second round of funding, according to peHUB. Called the Drug Engineering Process, its system helps research teams set and methodically achieve milestones across different areas, the company says. In its two case studies, it refined therapies for diabetes and HIV.
The funds came from Foundation Capital and Lanza TechVentures. Numerate has bagged $4 million to date.
Next Story: Cloudera closes $5M to deliver data mining software
Previous Story: Y Combinator gets a $2M shot in the arm from Sequoia, angels
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.